Bone involvement is a major concern for patients with multiple myeloma
70% to 95% of patients with advanced multiple myeloma will develop bone lesions, which may lead to bone complications or skeletal-related events (SREs)1*
51% of patients with multiple myeloma and osteolytic disease will develop an SRE without treatment2
*SREs are generally defined as pathologic fractures, spinal cord compression, radiation or surgery to bone, or tumour-induced hypercalcemia.3
Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.